-transparent.png){kind=logo}
Administration of the compound M&B 39890A lowered serum glucose levels significantly (p less than 0.001) in genetically obese mice, while no effect on serum insulin levels was observed. In in vitro experiments with isolated rat islets of Langerhans M&B 39890A inhibited arginine-stimulated glucagon release at all concentrations tested (0.5, 5.0 and 50 mumol/l). Insulin secretion was not inhibited by M&B 39890A (0.5 and 5.0 mumol/l), but was slightly decreased at 50 mumol/l. M&B 39890A (5 mumol/l) also inhibited glucagon secretion in vitro in the presence of 2 mmol/l, 6 mmol/l and 20 mmol/l glucose, while exerting no effect on insulin secretion. These results suggest that the hypoglycaemic action of M&B 39890A may be due to its direct and selective effect on glucagon secretion; this appears to operate by a mechanism different to that of glucose.
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
August 1976,
Diabetologia,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
February 1977,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
August 1969,
Archives internationales de physiologie et de biochimie,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
January 1991,
Hormone research,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
March 1987,
Molecular and cellular endocrinology,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
September 1988,
Journal of molecular endocrinology,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
October 1979,
Diabetes,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
January 1993,
Diabetes,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
July 1997,
Biochemical and biophysical research communications,
M Tadayyon, and
I Green, and
D Cook, and
J Pratt
January 1986,
The Biochemical journal,
